Noninvasive Opportunity Leuko is developing the first non-invasive white blood cell monitoring device for at-home use, presenting a clear sales path to hospitals, cancer centers, and home health providers seeking patient-friendly monitoring solutions for chemotherapy management and infection detection.

Clinical Partnerships Current and past collaborations with major cancer centers (Boston Medical Center, MD Anderson, Hospital 12 de Octubre) indicate strong interest from top-tier institutions, suggesting outreach targets in oncology departments and clinical trial networks for pilot deployments.

NIH Backing Recent $4.5M NIH NCI funding and SBIR phase IIb award validate technology viability and can be leveraged to secure co-development deals, grant-supported pilots, and larger scale purchasing agreements with large health systems.

Growth Signals Early revenue milestones and a funded trajectory imply readiness for early adopters in medtech devices; prioritize value propositions around reduced travel, faster results, and minimized invasive procedures to drive procurement conversations.

Global Reach With MIT-origin technology and a presence spanning Boston and Madrid, there is potential to target multinational cancer centers, academic medical networks, and international distributors seeking innovative WBC monitoring solutions.